Hims & Hers stock surged 10% after launching a compounded weight-loss pill for $49 per month, significantly undercutting Novo Nordisk's Wegovy. The generic version uses the same active ingredient but offers better absorption. The news pressured NVO shares down nearly 6% as cheaper competition enters the market.